Endoscopic evaluation of the effect of sucralfate therapy and other clinical parameters on the recurrence rate of gastric ulcers.
A randomized controlled clinical study was conducted to determine (a) whether basic aluminum sucrose sulfate (sucralfate) is effective in preventing or reducing gastric ulcer recurrence, and (b) the clinical parameters contributing to ulcer recurrence after endoscopically proved healing has been effected. A total of 167 patients were assigned on a random basis to either of two treatment groups, control (aluminum hydroxide and magnesium oxide) or sucralfate, and given these medications for 6 months. At the end of this period all medication was withdrawn from both groups and the patients were followed for an additional 12 months. Each patient was examined endoscopically at bimonthly intervals throughout the 18-month observation period. Treatment (sucralfate), ulcer history, size of previous ulcer(s), prestudy healing time, and prestudy healing stage attained (red or white scarring) were associated with a significant reduction in recurrence rate. Ulcer recurrence was markedly reduced in sucralfate patients as compared to control when the pretreatment ulcers had healed slowly (P less than 0.001).
D000328:Adult; D000368:Aged; D000535:Aluminum / Q000627:therapeutic use*; D000536:Aluminum Hydroxide / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004724:Endoscopy; D005260:Female; D006801:Humans; D008277:Magnesium Oxide / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D012008:Recurrence; D013276:Stomach Ulcer / Q000175:diagnosis / Q000188:drug therapy*; D013392:Sucralfate; D013395:Sucrose / Q000031:analogs & derivatives* / Q000627:therapeutic use
D008277:Magnesium Oxide; D013392:Sucralfate; D013395:Sucrose; D000536:Aluminum Hydroxide; D000535:Aluminum